Brazil has 713 deaths and 28,523 new cases in 24 hours


Covid: Brazil has 713 deaths and 28,523 new cases in 24 hours

Country is well positioned for access to vaccines; for researcher, already signed agreements provide alternatives.

Follow the Monitor on

Since the beginning of the pandemic, Brazil has accumulated 5,169,389 confirmed cases of Covid-19. Of this total, 89% of patients recovered from the disease, 2.9% died and 8.1% recovered. The data were released by the Ministry of Health on Thursday.

Brazil recorded 713 deaths in 24 hours, bringing the total number of deaths to 152,460. Another 2,360 deaths are under investigation.

The number of positive Covid-19 diagnoses increased by 28,523 in 24 hours. The number of recovered patients reaches 4,599,446. Currently, 417,480 Brazilians are undergoing treatment.

An assessment of the Covid-19 cases released yesterday afternoon by the State Department of Health showed that the State of São Paulo remained below the projections made by the Coronavirus Contingency Center for the first half of October. The Center projected that, until yesterday, the state would have between 1.10 million and 1.15 million confirmed cases of Covid-19 and between 38 thousand and 39 thousand deaths. According to the balance released this afternoon, the state of São Paulo has 1,051,613 confirmed cases of the new coronavirus, with 37,690 deaths. The daily numbers of deaths and new cases are still high in the state, but have been decelerating. The number of patients hospitalized in suspected or confirmed coronavirus cases currently totals 7,672 people in the state, also showing a downward trend. Of that total of hospitalized patients, 3,343 are hospitalized in serious condition. The occupancy rate of ICU beds is 41.9% in the state and 41.3% in Greater São Paulo.

Of the total cases diagnosed in the state, 934,547 people have recovered from the disease, 115,107 of them after hospitalization. Of the 645 municipalities in São Paulo, all of them register at least one confirmed case of the disease and, in 582 of them, at least one death was reported.

If ongoing clinical tests prove the efficacy of vaccines against Covid-19, Brazil is well positioned to obtain doses already next year, says professor at the Federal University of Goiás (UFG) Cristiana Toscano, who is part of the Advisory Group Strategy of Immunization Specialists (SAGE) of the World Health Organization (WHO).

The researcher explained that agreements already signed by the federal government and the state of São Paulo give alternatives to the country, but warns that it is necessary to hurry in planning to prepare the more than 30 thousand vaccination posts of the Unified Health System (SUS).

Last month, Brazil confirmed its participation in the Covax consortium, organized by the WHO to guarantee access to immunization worldwide. The fund expects to raise US $ 18 billion with the investment of 80 countries considered to be self-financing, such as Brazil, to supply the vaccines to these and another 92 countries that would not be able to manufacture or buy the doses. With the adhesion, the country will invest around R $ 2.5 billion and hopes to acquire a portfolio that, until then, has nine vaccines under development, to guarantee the protection of 10% of the population by the end of 2021.

In bilateral agreements, the country contracted the technology transfer of a British and a Chinese vaccine. The Federal Government signed an agreement with the developers of AstraZeneca and the University of Oxford for the Oswaldo Cruz Foundation to nationalize the production of the vaccine, which is in the last phase of clinical tests in several countries, including Brazil. The Oxford vaccine is also one of nine vaccines that make up the Covax portfolio.

In addition, the state government of São Paulo and the Butantan Institute signed an agreement for testing and transferring technology for the national production of the vaccine under development by the Chinese laboratory Sinovac.

Cristiana Toscano pointed out that, due to the pandemic, investments in production had to be anticipated, which implies the risk that vaccines will not be proven effective. As well as tests and regulatory processes, the researcher points out that planning to make vaccines arrive at the health centers also needs to be streamlined from the local to the national level, because there is a horizon for the start of immunization in the first months of the year. comes.

“You don’t have to wait. You don’t have a moment to say ‘now let’s start’. Now it’s over. We are working with an optimistic and hopeful forecast. If, in fact, in this preliminary December assessment, these vaccines demonstrate efficacy and safety , the forecast is that between February and March, at the latest, it is indeed possible to start the vaccination. We are talking about a very short time to prepare everything for a vaccination of such scale and tremendous importance “.

With information from Agência Brasil

Follow the Monitor on


Please enter your comment!
Please enter your name here